Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study by Wolfhagen, F.H.J. (Franciscus) et al.
GASTROENTEROLOGY 1997;113:1264 –1269
Oral Naltrexone Treatment for Cholestatic Pruritus: A Double-
Blind, Placebo-Controlled Study
FRANK H. J. WOLFHAGEN,* EMILIO STERNIERI, ‡ WIM C. J. HOP,§ GIOVANNI VITALE, ‡
MARCO BERTOLOTTI, ‡ and HENK R. VAN BUUREN*
*Department of Hepatogastroenterology, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands; ‡Department of Clinical
Pharmacology, University of Modena, Modena, Italy; and §Department of Biostatistics, Erasmus University, Rotterdam, The Netherlands
Background & Aims: The efficacy of currently available Recent studies on the role of the central nervous sys-
therapeutic agents for cholestatic pruritus is often dis- tem in cholestatic itching indicate that endogenous opi-
appointing. The aim of this study was to assess the ate substances of the enkephalin class, in particular, may
antipruritic effect of naltrexone, an oral opiate receptor be potential mediators.12,13 Accumulating evidence sup-
antagonist. Methods: Sixteen patients with pruritus of ports this theory: opiates have been found to induce nal-
chronic cholestasis were randomized to receive naltrex- oxone-reversible pruritus14; plasma levels of enkephalins,
one (4-week course of 50 mg naltrexone daily) or pla- which can pass the blood-brain barrier,15–17 are elevated
cebo. Pruritus, quality of sleep, fatigue (using visual
in chronic cholestatic liver disease18–20 and in rats with
analogue scales), side effects, and liver function were
a resected bile duct21; and naloxone reversible itchingassessed every 2 weeks. Serum naltrexone and 6b-
can be induced in monkeys by injecting plasma fromnaltrexol concentrations in all patients and 5 healthy
cholestatic patients with pruritus into the medullary dor-controls were measured during the first day of naltrex-
sal horn.22 Moreover, treatment with opiate antagonistsone treatment. Results: Mean changes with respect
(i.e., naloxone, nalmefene) of patients with primary bili-to baseline were significantly different, in favor of the
ary cirrhosis (PBC) has led to impressive amelioration ofnaltrexone group, for daytime itching (054% vs. 8%; P
 0.001) and nighttime itching (044% vs. 7%, P  the itching.13,23–25 However, the drugs investigated have
0.003). In 4 naltrexone-treated patients, side effects important limitations. Naloxone has a short half-life and
(transient in 3 cases) consistent with an opiate with- can only be administered parenterally. Nalmefene treat-
drawal syndrome were noted. No deterioration of the ment is associated with a severe opiate withdrawal-like
underlying disease was observed. Naltrexone and 6b- (‘‘cold-turkey’’) syndrome,13 and is currently available for
naltrexol levels did not differ between patients and con- experimental use only.
trols, and there was no significant association with Naltrexone (N-cyclopropylmethylnoroxymorphone),
treatment response. Conclusions: For patients with
an opiate receptor antagonist that can be administeredcholestatic liver disease and itching, refractory to regu-
orally, is being used to treat opiate addiction. It is alar antipruritic therapy, oral naltrexone may be an effec-
structural analogue of naloxone and nalmefene with ative and well-tolerated alternative.
bioavailability and half-life that lie between those of the
former two. Naltrexone undergoes extensive (95%) first-
P pass metabolism. The main metabolite is 6b-naltrexol,ruritus is a common and occasionally disablingsymptom in patients with chronic cholestatic liver which exerts minimal but long-lasting opiate antagonist
disease. Clinical experience over the last decades indicates activity and reaches much higher plasma levels than the
that patients with pruritus may benefit from treatment parent drug. Clearance is mainly via the renal route.26,27
with bile salt–binding resins1–5 or rifampicin.6,7 The We initiated a randomized, double-blind, placebo-
efficacy of these agents is unpredictable, and side effects controlled trial to assess the antipruritic effects and toler-
are not uncommon.5,8 The efficacy of a variety of other ance of naltrexone in patients with chronic cholestatic
agents including antihistamines and ursodeoxycholic liver disease.
acid has not been demonstrated convincingly.9,10 In a
Abbreviations used in this paper: AUC, area under the curve; PBC,minority of cases, itching may be so aggravating that
primary biliary cirrhosis; PSC, primary sclerosing cholangitis; VAS,other therapeutic modalities, including plasmapheresis,
visual analogue scale.
hemoperfusion, biliary drainage, and ultimately liver q 1997 by the American Gastroenterological Association
0016-5085/97/$3.00transplantation, are indicated.1–4,11
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Italy) packed with 5 mm octadecylisilane was used. The areaMaterials and Methods
under the curve (AUC) of the plasma concentrations of naltrex-
Patients one and 6b-naltrexol was calculated according to the trapezoi-
dal rule, restricted to the time interval of experimental sam-On the basis of power calculations, 16 patients were
ples.included in this study: 13 with PBC, 2 with primary sclerosing
cholangitis (PSC), and 1 with features suggesting PSC who
Assessment of the Perception of Pruritusrefused to undergo diagnostic endoscopic retrograde cholangio-
pancreatography. All patients had persistent generalized pruri- Throughout the study, patients scored the severity of
tus without major fluctuations or symptom-free periods during pruritus each day on visual analogue scales (VAS). Separate
the preceding 3 months. In all cases, the following conditions scales for itching during the day (from awakening to going to
were excluded: use of opiates or deterioration of liver function bed) and night had to be completed before going to bed and
test results during the last 3 months, renal failure (creatinine after awakening, respectively. The scales were designed ac-
 150 mmol/L), changes in antipruritic medication (e.g., cording to standard principles30 and consisted of 100-mm hori-
cholestyramine, rifampicin, antihistamines, ursodeoxycholic zontal lines, without marks, on which the patient was asked
acid) within 1 month of entry, and pruritus primarily due to to indicate the severity of itching. The left side (0 mm) was
a nonhepatological disorder. Comedication could be continued labeled ‘‘no itching’’ and the right side (100 mm) ‘‘unbearable
unaltered. itching.’’ Similar VAS were used for the quality of sleep (slept
The study was performed from March to December 1994 all night–no sleep at all; to be filled in upon awakening)
at the University Hospital Rotterdam. All patients were inhab- and fatigue (no tiredness–severely tired; to be completed at
itants of the Netherlands and gave written informed consent. bedtime).
The study was approved by the Medical Ethics Committee of
the University Hospital Rotterdam. Statistical Analyses
The mean of the values of the VAS scores for the 5Design of the Study
days preceding each visit was used for analysis of symptoms.
After a 2-week period in which baseline scores were Paired and unpaired t tests or their nonparametric equivalents,
obtained, patients were randomly assigned (using opaque enve- where appropriate, were used. In addition to comparison of
lopes) to receive capsules containing either 25 mg naltrexone the two treatment groups, analysis of covariance was used to
(Nalorex, Dupont Merck, Wilmington, DE) or placebo for 4 adjust for some differences in baseline characteristics. Correla-
weeks. On the first day, medication was given in two doses of tions were determined by Spearman’s rank correlation test (Rs).
25 mg, each 2 hours apart; subsequently, the patient received All analyses were performed according to the intention-to-
50 mg naltrexone or placebo once daily. treat principle. A two-sided P value of ¡0.05 was considered
All patients were seen by the same physician (F.H.J.W.), significant.
twice before randomization and 2 and 4 weeks after the start
Resultsof treatment. At each visit, the occurrence of adverse events,
particularly withdrawal-like symptoms,28 blood pressure, heart Baseline characteristics are presented in Table 1.
rate, and liver function (bilirubin, transaminases, alkaline In the naltrexone group, the liver function tests at entry
phosphatase), were assessed. At the start and end of treatment,
seemed to be increased and the baseline pruritus scoresserum creatinine, albumin, and total bile salt levels and pro-
were slightly higher compared with the placebo group.thrombin time were measured.
In the naltrexone group, the dose was decreased to 25Patients were admitted to the hospital during the first 8
mg for 1 patient on the seventh day due to side effects,hours (9 AM to 5 PM) of treatment for continuous monitoring
and 1 patient withdrew after 2 weeks because itchingof vital signs and adverse effects. Before the first dose, and at
increased. The latter patient was subsequently treated2 (i.e., before the second dose), 4, and 8 hours serum aliquots
were drawn and stored at 0207C until the concentrations of with rifampicin, which resulted in a decrease in pruritus.
naltrexone and its major metabolite, 6b-naltrexol, could be Treatment compliance, assessed by pill counts, was
assayed. Control data on naltrexone and 6b-naltrexol levels 100%.
were obtained from 5 healthy controls (2 men; median age,
49 years; range, 30–60 years) who consented to take naltrexone Effects on Symptoms
for 1 day, according to the same schedule.
Visual analogue scores for daytime and nighttimeDrug assays were performed according to Zuccaro et al.29
pruritus, quality of sleep, and fatigue are presented inwith minor modifications using a Beckman System Gold High
Figures 1–4. Table 2 shows the differences in percentagePerformance Liquid Chromatograph equipped with a diode
change in these variables after 4 weeks of treatment; allarray detector module 168, set at 202 nm (Beckman Instru-
changes were greater in the naltrexone group than thements Inc., San Ramon, CA). A reversed-phase C-18 25 cm
1 4.6 mm Hypersil column (Labservice Analytical, Bologna, placebo group. The changes in the pruritus scores were
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Table 1. Patient Characteristics at Entry
Naltrexone Placebo
(n  8) (n  8)
Female/male 7/1 5/3
PBC/PSC/unclassifie 8/—/— 5/2/1
Child –Pugh class A/B/C 7/0/1 7/1/0
Age (yr) (range) 58 (37–72) 46 (43–74)
Bilirubin (N, 14 mmol/L) 50 (14–435) 17 (8–94)
Alkaline phosphatase
(N, 75 U/L) 410 (256–583) 187 (64–512)
ALT (N, 30 U/L) 72 (22–302) 77 (7–80)
Serum bile salts
(N, 10 mmol/L) 225 (15–420) 71 (34–340)
Daytime pruritus (VAS) 65 (52–93) 48 (18–80)
Nighttime pruritus (VAS) 59 (8–92) 47 (7–80) Figure 2. Severity of itching during the night for patients treated with
Scratch lesions 7 8 (A ) naltrexone or (B) placebo. Significan differences with respect to
Previous antipruritic treatment baseline were found for the treatment group only (P  0.02). Hori-
Ursodeoxycholic acid 8 (6)a 8 (7)a zontal lines indicate means. s, Patient treated for 2 weeks.
Anion binders 7 (1)a 7
Antihistamines 3 3
Rifampicin 2 2
Light therapy 2 0 In the naltrexone group, improvements in nighttime
Plasmapheresis 1 0
itching correlated well with the decrease in disturbedOther 0 1
sleep (Rs  0.93; P  0.0001) and showed a trend with
NOTE. Results are expressed in number of patients or median (range).
reduced fatigue (Rs  0.71; P  0.2).ALT, alanine aminotransferase; N, upper limit of normal.
aTreatment continued. For 5 of the 8 patients of the naltrexone group, the
total pruritus score (i.e., the sum of the day and night
scores) was reduced to half or less (the percentage decrease
already significant at 2 weeks (all P ¡ 0.04). When the ranged from 49% to 93%) after 4 weeks of treatment.
values for the patient who discontinued therapy at 2 Eventually, 2 patients were completely free of itching.
weeks were included at 4 weeks, the results did not In the placebo group, the maximum decrease was 21%.
change significantly. Adjustment for baseline differences The time of onset of the improvement in itching varied.
in symptom scores, bilirubin, alkaline phosphatase, and For the 3 patients who exhibited the most dramatic re-
serum bile salt levels as well as age did not have a major sults, the effect was already apparent during the first
effect on these results; only the difference in the changes day, whereas in the other responders the effect gradually
in fatigue failed to reach statistical significance after ad- became apparent over a period of 1–3 weeks.
justing for these factors.
Side Effects and Safety of Treatment
Four patients in the treatment group experienced
an initial period of general malaise, associated with nau-
sea (4 patients), dizziness (3), flushing (2), drowsiness
(2), headache (1), nightmares (1), and tremor (1). These
symptoms developed within the first 2 days and subsided
or greatly improved after about 3 days, without addi-
tional treatment or withdrawal of medication. In 1 pa-
tient, the symptoms persisted and reduction of the dose
to 25 mg/day after 1 week provided some relief, but the
symptoms did not disappear. Six patients (5 naltrexone,
1 placebo) reported mild abdominal cramps, which in
general were present during the whole treatment period.
Other symptoms noted were dry mouth (naltrexone, 2;
Figure 1. Severity of itching during the day for patients treated with placebo, 1), increased peripheral edema (naltrexone, 1),
(A ) naltrexone or (B) placebo. Significan differences with respect to
night-sweating (naltrexone, 1), irritability (placebo, 1),baseline were found for the treatment group only (P  0.001). Hori-
zontal lines indicate means. s, Patient treated for 2 weeks. epistaxis (placebo, 1), and swelling of the hands (placebo,
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1). There were no significant differences between the two
groups in changes in blood pressure or pulse rate.
A negative effect of naltrexone on the underlying liver
disease did not occur as indicated by clinical changes
or effects on serum transaminase, alkaline phosphatase,
bilirubin, and bile salt levels.
Plasma Levels of Naltrexone
and 6b-Naltrexol
Complete data on naltrexone and 6b-naltrexol lev-
els were obtained for 6 patients. There were no differences
between healthy controls and patients in naltrexone and
Figure 4. Severity of fatigue for patients treated with (A ) naltrexone6b-naltrexol serum concentrations, summarized as the
or (B) placebo. Significan differences with respect to baseline wereAUC for these compounds during the first 8 hours of
found for the treatment group only (P 0.01). Horizontal lines indicate
therapy (Figure 5). Moreover, there were no correlations means. s, Patient treated for 2 weeks.
between the AUC for naltrexone or the 6b-naltrexol lev-
els and changes in pruritus scores.
It has been suggested that the measurement of itching
Discussion by VAS is inferior to more sophisticated and objective
methods that quantify actual scratching activity.24 ApartThis study shows that treatment with the oral
from the practical difficulties of using these devices foropiate receptor antagonist naltrexone relieves the itching
ambulant patients during prolonged follow-up, we be-associated with cholestatic liver diseases. The reduction
lieve that the main goal of pruritus treatment is to im-in itching is associated with an improved quality of sleep.
prove the patient’s well-being and quality of life, whichThe observed difference at entry between the groups
only can be measured subjectively.in bilirubin, serum bile salts, and alkaline phosphatase
In this study, 5 of 8 treated patients suffered consider-levels did not influence the outcome of this trial, as
ably less itching. One, however, experienced a recurrenceshown by analysis of covariance. These variables were not
of pruritus after an initial dramatic decrease. This hassignificantly related to either the baseline pruritus scores
been observed occasionally by others during treatmentor the observed improvements. This is in agreement with
with nalmefene (Bergasa NV, personal communication,literature data indicating that there is no clear relation-
May 1995) and naltrexone.34 One might speculate thatship between itching and the severity of liver function
during cholestasis, opiate receptors in the brain are down-abnormalities in cholestatic disorders, although the de-
regulated due to enhanced opioid stimulation. The re-velopment of pruritus becomes more likely as jaundice
verse, up-regulation of opiate receptors might occurprogresses.31-33
during naltrexone treatment, resulting in an increased
sensitivity to endogenous opioids.17 Carson et al. recently
suggested that recurrence of pruritus can be prevented
by interrupting treatment for 2 days every week.34
It is unclear why some patients respond to opiate re-
ceptor antagonists while others do not. Our data on se-
rum naltrexone and 6b-naltrexol levels indicate that this
is unlikely to be a result of impaired uptake or metabo-
lism of naltrexone in cholestatic patients. Moreover, nal-
trexone exerts pharmacological effects in responders and
nonresponders, as indicated by the occurrence of side
effects in both groups. It seems unlikely that the naltrex-
one dose was too low. Heroin challenge and receptor
binding studies have shown that a 50-mg dose of oral
naltrexone provides sufficient opiate protection for 24
Figure 3. Severity of disturbed sleep for patients treated with (A ) hours.26,35 Moreover, our preliminary experience with the
naltrexone or (B) placebo. Significan differences with respect to base-
administration of higher doses does not suggest a majorline were found for the treatment group only (P  0.02). Horizontal
lines indicate means. s, Patient treated for 2 weeks. enhancement of effect.
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Table 2. Percentage Change { SEM in VAS Scores at 4 Weeks Compared With Baseline
% Change { SEM
Mean difference
Naltrexone Placebo (95% CI) P valuea
Itching
Daytime 054 { 10 8 { 10 62 (32–92) 0.001 (0.042)
Nighttime 044 { 11 7 { 9 51 (20–82) 0.003 (0.019)
Sleep disturbance 042 { 9 22 { 16 64 (24–104) 0.004 (0.010)
Fatigue 031 { 8 27 { 18 58 (14–102) 0.01 (0.23)
CI, confidenc interval.
aP values adjusted for age, baseline VAS, serum bilirubin, alkaline phosphatase, and bile salts are given in parentheses.
The results of the present study are consistent with In patients without hepatic disorders, high doses of
naltrexone (300 mg/day), but not low doses (50 mg/day),those reported in one small, uncontrolled study with
naltrexone34 and two placebo-controlled, crossover stud- have been reported to induce liver function abnormali-
ties.38 This was not observed in other studies for loweries of 8 and 29 patients, respectively, on 24-hour nalox-
one infusions24,25; the latter yielded a reduction in itch doses of naltrexone in patients with and without liver
disease.39–41 We found no evidence of a negative effectperception of about 50%. Two studies have suggested
that nalmefene may be more powerful in relieving itch- of naltrexone on liver function. Thus, currently available
data suggest that naltrexone can be administered safelying.13,23 However, the side effects seemed to be more
severe and more frequent. In our study, half of the pa- to patients with liver disorders.
In conclusion, naltrexone seems to be an effective alter-tients experienced side effects consistent with opiate
withdrawal,13,28 but none of these symptoms led to treat- native for patients with cholestatic pruritus, which does
not respond to other therapeutic modalities such as bilement withdrawal; the symptoms had subsided to a large
extent after the third day of treatment. Hemodynamic salt–binding resins, rifampicin, and antihistamines. The
lack of response to naltrexone in some cases does not seemchanges (i.e., increased blood pressure and decreased
pulse rate, as noted in the British nalmefene study13) were to be caused by impaired gastrointestinal absorption or
metabolism of naltrexone. The long-term benefit/risk ra-not observed. Side effects generally developed during the
second day of treatment, but the nalmefene-induced tio for opiate receptor antagonist treatment remains to
be established.symptoms were apparent within 1 hour of the first dose.13
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